nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—SLC6A3—attention deficit hyperactivity disorder	0.246	0.303	CbGaD
Nefazodone—ADRA2A—attention deficit hyperactivity disorder	0.241	0.297	CbGaD
Nefazodone—SLC6A4—attention deficit hyperactivity disorder	0.184	0.226	CbGaD
Nefazodone—HTR2A—attention deficit hyperactivity disorder	0.141	0.174	CbGaD
Nefazodone—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.00799	0.15	CbGeAlD
Nefazodone—HTR2A—locus ceruleus—attention deficit hyperactivity disorder	0.00481	0.0899	CbGeAlD
Nefazodone—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.00425	0.0795	CbGeAlD
Nefazodone—HTR2A—autonomic nervous system—attention deficit hyperactivity disorder	0.00255	0.0478	CbGeAlD
Nefazodone—SLC6A3—forebrain—attention deficit hyperactivity disorder	0.00123	0.023	CbGeAlD
Nefazodone—HTR2C—forebrain—attention deficit hyperactivity disorder	0.00119	0.0222	CbGeAlD
Nefazodone—SLC6A4—forebrain—attention deficit hyperactivity disorder	0.00112	0.021	CbGeAlD
Nefazodone—HTR1A—forebrain—attention deficit hyperactivity disorder	0.000998	0.0187	CbGeAlD
Nefazodone—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.00099	0.0185	CbGeAlD
Nefazodone—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.00092	0.0172	CbGeAlD
Nefazodone—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.000889	0.0166	CbGeAlD
Nefazodone—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.000856	0.016	CbGeAlD
Nefazodone—HTR1A—cardiovascular system—attention deficit hyperactivity disorder	0.000844	0.0158	CbGeAlD
Nefazodone—SLC6A3—midbrain—attention deficit hyperactivity disorder	0.00081	0.0152	CbGeAlD
Nefazodone—HTR2C—midbrain—attention deficit hyperactivity disorder	0.000783	0.0147	CbGeAlD
Nefazodone—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.000778	0.0146	CbGeAlD
Nefazodone—SLC6A4—midbrain—attention deficit hyperactivity disorder	0.000743	0.0139	CbGeAlD
Nefazodone—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.0007	0.0131	CbGeAlD
Nefazodone—ADRA1B—brain—attention deficit hyperactivity disorder	0.00068	0.0127	CbGeAlD
Nefazodone—SLC6A3—nervous system—attention deficit hyperactivity disorder	0.000666	0.0125	CbGeAlD
Nefazodone—HTR1A—midbrain—attention deficit hyperactivity disorder	0.000659	0.0123	CbGeAlD
Nefazodone—HTR2C—nervous system—attention deficit hyperactivity disorder	0.000644	0.0121	CbGeAlD
Nefazodone—SLC6A3—central nervous system—attention deficit hyperactivity disorder	0.000641	0.012	CbGeAlD
Nefazodone—SLC6A3—cerebellum—attention deficit hyperactivity disorder	0.000627	0.0117	CbGeAlD
Nefazodone—HTR2C—central nervous system—attention deficit hyperactivity disorder	0.00062	0.0116	CbGeAlD
Nefazodone—SLC6A4—nervous system—attention deficit hyperactivity disorder	0.00061	0.0114	CbGeAlD
Nefazodone—HTR2A—forebrain—attention deficit hyperactivity disorder	0.000595	0.0111	CbGeAlD
Nefazodone—SLC6A4—central nervous system—attention deficit hyperactivity disorder	0.000588	0.011	CbGeAlD
Nefazodone—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000542	0.0101	CbGeAlD
Nefazodone—HTR1A—nervous system—attention deficit hyperactivity disorder	0.000542	0.0101	CbGeAlD
Nefazodone—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.000537	0.0101	CbGeAlD
Nefazodone—HTR1A—central nervous system—attention deficit hyperactivity disorder	0.000522	0.00977	CbGeAlD
Nefazodone—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.000517	0.00968	CbGeAlD
Nefazodone—Zuclopenthixol—DRD5—attention deficit hyperactivity disorder	0.000515	0.0601	CrCbGaD
Nefazodone—HTR1A—cerebellum—attention deficit hyperactivity disorder	0.00051	0.00955	CbGeAlD
Nefazodone—SLC6A3—brain—attention deficit hyperactivity disorder	0.000509	0.00953	CbGeAlD
Nefazodone—HTR2A—cardiovascular system—attention deficit hyperactivity disorder	0.000503	0.00942	CbGeAlD
Nefazodone—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.0005	0.00935	CbGeAlD
Nefazodone—HTR2C—brain—attention deficit hyperactivity disorder	0.000492	0.00921	CbGeAlD
Nefazodone—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000481	0.009	CbGeAlD
Nefazodone—Aripiprazole—DRD5—attention deficit hyperactivity disorder	0.000476	0.0555	CrCbGaD
Nefazodone—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.00047	0.0088	CbGeAlD
Nefazodone—SLC6A4—brain—attention deficit hyperactivity disorder	0.000467	0.00873	CbGeAlD
Nefazodone—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000462	0.00865	CbGeAlD
Nefazodone—Aripiprazole—ADRA2C—attention deficit hyperactivity disorder	0.000449	0.0524	CrCbGaD
Nefazodone—HTR1A—brain—attention deficit hyperactivity disorder	0.000414	0.00775	CbGeAlD
Nefazodone—SLC6A2—brain—attention deficit hyperactivity disorder	0.000411	0.00769	CbGeAlD
Nefazodone—HTR2A—midbrain—attention deficit hyperactivity disorder	0.000393	0.00735	CbGeAlD
Nefazodone—ABCB1—forebrain—attention deficit hyperactivity disorder	0.00039	0.0073	CbGeAlD
Nefazodone—ADRA1A—brain—attention deficit hyperactivity disorder	0.000382	0.00715	CbGeAlD
Nefazodone—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.00038	0.00711	CbGeAlD
Nefazodone—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000366	0.00685	CbGeAlD
Nefazodone—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000357	0.00669	CbGeAlD
Nefazodone—Acetophenazine—DRD1—attention deficit hyperactivity disorder	0.000353	0.0411	CrCbGaD
Nefazodone—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.00033	0.00617	CbGeAlD
Nefazodone—HTR2A—nervous system—attention deficit hyperactivity disorder	0.000323	0.00605	CbGeAlD
Nefazodone—HTR2A—central nervous system—attention deficit hyperactivity disorder	0.000311	0.00582	CbGeAlD
Nefazodone—HTR2A—cerebellum—attention deficit hyperactivity disorder	0.000304	0.00569	CbGeAlD
Nefazodone—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000299	0.0056	CbGeAlD
Nefazodone—Quetiapine—DRD5—attention deficit hyperactivity disorder	0.000298	0.0347	CrCbGaD
Nefazodone—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000294	0.00551	CbGeAlD
Nefazodone—ADRA2A—brain—attention deficit hyperactivity disorder	0.00029	0.00543	CbGeAlD
Nefazodone—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000288	0.00539	CbGeAlD
Nefazodone—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000283	0.0053	CbGeAlD
Nefazodone—Quetiapine—ADRA2C—attention deficit hyperactivity disorder	0.000281	0.0327	CrCbGaD
Nefazodone—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000277	0.00518	CbGeAlD
Nefazodone—Domperidone—DRD3—attention deficit hyperactivity disorder	0.000272	0.0317	CrCbGaD
Nefazodone—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000257	0.00482	CbGeAlD
Nefazodone—Acetophenazine—DRD2—attention deficit hyperactivity disorder	0.000249	0.029	CrCbGaD
Nefazodone—HTR2A—brain—attention deficit hyperactivity disorder	0.000247	0.00462	CbGeAlD
Nefazodone—Aripiprazole—DRD4—attention deficit hyperactivity disorder	0.000244	0.0284	CrCbGaD
Nefazodone—CYP2D6—brain—attention deficit hyperactivity disorder	0.000225	0.00421	CbGeAlD
Nefazodone—Zuclopenthixol—DRD1—attention deficit hyperactivity disorder	0.000223	0.026	CrCbGaD
Nefazodone—Aripiprazole—HTR1B—attention deficit hyperactivity disorder	0.000216	0.0252	CrCbGaD
Nefazodone—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000212	0.00396	CbGeAlD
Nefazodone—Aripiprazole—DRD3—attention deficit hyperactivity disorder	0.00021	0.0245	CrCbGaD
Nefazodone—Zuclopenthixol—ADRA2A—attention deficit hyperactivity disorder	0.000207	0.0242	CrCbGaD
Nefazodone—Aripiprazole—DRD1—attention deficit hyperactivity disorder	0.000206	0.024	CrCbGaD
Nefazodone—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.000204	0.00381	CbGeAlD
Nefazodone—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000199	0.00373	CbGeAlD
Nefazodone—Thioproperazine—DRD1—attention deficit hyperactivity disorder	0.000196	0.0228	CrCbGaD
Nefazodone—Aripiprazole—ADRA2A—attention deficit hyperactivity disorder	0.000192	0.0223	CrCbGaD
Nefazodone—Trazodone—ADRA2A—attention deficit hyperactivity disorder	0.000191	0.0222	CrCbGaD
Nefazodone—Domperidone—DRD2—attention deficit hyperactivity disorder	0.000188	0.022	CrCbGaD
Nefazodone—Prochlorperazine—DRD3—attention deficit hyperactivity disorder	0.000187	0.0218	CrCbGaD
Nefazodone—Fluphenazine—DRD3—attention deficit hyperactivity disorder	0.000169	0.0197	CrCbGaD
Nefazodone—Fluphenazine—DRD1—attention deficit hyperactivity disorder	0.000166	0.0194	CrCbGaD
Nefazodone—ABCB1—brain—attention deficit hyperactivity disorder	0.000162	0.00303	CbGeAlD
Nefazodone—Zuclopenthixol—DRD2—attention deficit hyperactivity disorder	0.000157	0.0183	CrCbGaD
Nefazodone—Fluphenazine—ADRA2A—attention deficit hyperactivity disorder	0.000155	0.018	CrCbGaD
Nefazodone—Quetiapine—DRD4—attention deficit hyperactivity disorder	0.000152	0.0178	CrCbGaD
Nefazodone—Aripiprazole—SLC6A4—attention deficit hyperactivity disorder	0.000146	0.017	CrCbGaD
Nefazodone—Trazodone—SLC6A4—attention deficit hyperactivity disorder	0.000146	0.017	CrCbGaD
Nefazodone—Aripiprazole—DRD2—attention deficit hyperactivity disorder	0.000145	0.017	CrCbGaD
Nefazodone—Thioproperazine—DRD2—attention deficit hyperactivity disorder	0.000138	0.0161	CrCbGaD
Nefazodone—Quetiapine—HTR1B—attention deficit hyperactivity disorder	0.000135	0.0158	CrCbGaD
Nefazodone—Perphenazine—DRD1—attention deficit hyperactivity disorder	0.000131	0.0153	CrCbGaD
Nefazodone—Quetiapine—DRD3—attention deficit hyperactivity disorder	0.000131	0.0153	CrCbGaD
Nefazodone—Prochlorperazine—DRD2—attention deficit hyperactivity disorder	0.00013	0.0151	CrCbGaD
Nefazodone—Quetiapine—DRD1—attention deficit hyperactivity disorder	0.000129	0.015	CrCbGaD
Nefazodone—Perphenazine—ADRA2A—attention deficit hyperactivity disorder	0.000122	0.0142	CrCbGaD
Nefazodone—Zuclopenthixol—HTR2A—attention deficit hyperactivity disorder	0.000122	0.0142	CrCbGaD
Nefazodone—Quetiapine—ADRA2A—attention deficit hyperactivity disorder	0.00012	0.014	CrCbGaD
Nefazodone—Fluphenazine—DRD2—attention deficit hyperactivity disorder	0.000117	0.0137	CrCbGaD
Nefazodone—Aripiprazole—HTR2A—attention deficit hyperactivity disorder	0.000112	0.0131	CrCbGaD
Nefazodone—Trazodone—HTR2A—attention deficit hyperactivity disorder	0.000112	0.013	CrCbGaD
Nefazodone—Thioproperazine—HTR2A—attention deficit hyperactivity disorder	0.000107	0.0124	CrCbGaD
Nefazodone—Trifluoperazine—DRD2—attention deficit hyperactivity disorder	9.37e-05	0.0109	CrCbGaD
Nefazodone—Perphenazine—DRD2—attention deficit hyperactivity disorder	9.27e-05	0.0108	CrCbGaD
Nefazodone—Quetiapine—DRD2—attention deficit hyperactivity disorder	9.09e-05	0.0106	CrCbGaD
Nefazodone—Fluphenazine—HTR2A—attention deficit hyperactivity disorder	9.06e-05	0.0106	CrCbGaD
Nefazodone—Trifluoperazine—HTR2A—attention deficit hyperactivity disorder	7.24e-05	0.00844	CrCbGaD
Nefazodone—Perphenazine—HTR2A—attention deficit hyperactivity disorder	7.16e-05	0.00835	CrCbGaD
Nefazodone—Quetiapine—HTR2A—attention deficit hyperactivity disorder	7.02e-05	0.00819	CrCbGaD
Nefazodone—ADRA1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.4e-05	0.000348	CbGpPWpGaD
Nefazodone—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	4.38e-05	0.000347	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	4.38e-05	0.000347	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	4.34e-05	0.000343	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	4.25e-05	0.000336	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.2e-05	0.000332	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.13e-05	0.000326	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.11e-05	0.000325	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.1e-05	0.000325	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.08e-05	0.000323	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.04e-05	0.00032	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.93e-05	0.000311	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.88e-05	0.000307	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	3.82e-05	0.000302	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	3.82e-05	0.000302	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.79e-05	0.0003	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.77e-05	0.000299	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	3.76e-05	0.000297	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.75e-05	0.000296	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.73e-05	0.000295	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.64e-05	0.000288	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.62e-05	0.000287	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.61e-05	0.000286	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.61e-05	0.000285	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.59e-05	0.000284	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.57e-05	0.000282	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.56e-05	0.000282	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.49e-05	0.000276	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.47e-05	0.000274	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.43e-05	0.000272	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.35e-05	0.000265	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.34e-05	0.000264	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.28e-05	0.000259	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.27e-05	0.000259	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.26e-05	0.000258	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.26e-05	0.000258	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.25e-05	0.000257	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.24e-05	0.000257	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.24e-05	0.000257	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.24e-05	0.000256	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.23e-05	0.000256	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.21e-05	0.000254	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.19e-05	0.000253	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.19e-05	0.000253	CbGpPWpGaD
Nefazodone—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	3.19e-05	0.000253	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.19e-05	0.000253	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.18e-05	0.000251	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.17e-05	0.000251	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.17e-05	0.000251	CbGpPWpGaD
Nefazodone—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	3.17e-05	0.000251	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.15e-05	0.000249	CbGpPWpGaD
Nefazodone—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	3.15e-05	0.000249	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.14e-05	0.000248	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.13e-05	0.000248	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.12e-05	0.000247	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.12e-05	0.000247	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.11e-05	0.000247	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.1e-05	0.000246	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.09e-05	0.000245	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.08e-05	0.000244	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.06e-05	0.000242	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.05e-05	0.000241	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.04e-05	0.000241	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.04e-05	0.000241	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.04e-05	0.000241	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.03e-05	0.00024	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3e-05	0.000238	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.98e-05	0.000236	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	2.98e-05	0.000236	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.95e-05	0.000233	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	2.94e-05	0.000233	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.94e-05	0.000232	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.93e-05	0.000232	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.92e-05	0.000231	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.9e-05	0.000229	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.9e-05	0.000229	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.9e-05	0.000229	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.88e-05	0.000228	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.86e-05	0.000227	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	2.86e-05	0.000226	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.85e-05	0.000225	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.84e-05	0.000224	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	2.83e-05	0.000224	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.83e-05	0.000224	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.82e-05	0.000223	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.81e-05	0.000222	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.81e-05	0.000222	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.8e-05	0.000222	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.8e-05	0.000221	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.77e-05	0.000219	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.76e-05	0.000218	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.76e-05	0.000218	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.76e-05	0.000218	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.76e-05	0.000218	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.75e-05	0.000217	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.73e-05	0.000216	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.72e-05	0.000215	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.7e-05	0.000214	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.7e-05	0.000214	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.7e-05	0.000214	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—TPH2—attention deficit hyperactivity disorder	2.68e-05	0.000212	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.68e-05	0.000212	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.67e-05	0.000211	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.67e-05	0.000211	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.65e-05	0.00021	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.65e-05	0.00021	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—DPYD—attention deficit hyperactivity disorder	2.64e-05	0.000209	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.63e-05	0.000209	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.63e-05	0.000208	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.58e-05	0.000204	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.57e-05	0.000204	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.56e-05	0.000203	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.55e-05	0.000202	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.55e-05	0.000202	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.54e-05	0.000201	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.54e-05	0.000201	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.51e-05	0.000199	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.5e-05	0.000198	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.49e-05	0.000197	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.48e-05	0.000197	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.48e-05	0.000196	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.47e-05	0.000196	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.46e-05	0.000195	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.45e-05	0.000194	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.45e-05	0.000194	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.42e-05	0.000192	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.39e-05	0.000189	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.32e-05	0.000183	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.31e-05	0.000183	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.3e-05	0.000182	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.26e-05	0.000179	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.25e-05	0.000178	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	2.22e-05	0.000176	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.21e-05	0.000175	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.2e-05	0.000174	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.14e-05	0.00017	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.12e-05	0.000168	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	2.11e-05	0.000167	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.11e-05	0.000167	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.11e-05	0.000167	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.1e-05	0.000166	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	2.08e-05	0.000165	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.06e-05	0.000163	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.05e-05	0.000162	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	2.04e-05	0.000162	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.04e-05	0.000161	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2e-05	0.000158	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.96e-05	0.000155	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	1.94e-05	0.000153	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.94e-05	0.000153	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.93e-05	0.000153	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.93e-05	0.000153	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.92e-05	0.000152	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.91e-05	0.000151	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	1.91e-05	0.000151	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.87e-05	0.000148	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.87e-05	0.000148	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.86e-05	0.000147	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.84e-05	0.000146	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.8e-05	0.000142	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.79e-05	0.000142	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.78e-05	0.000141	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.77e-05	0.00014	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.74e-05	0.000138	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.74e-05	0.000138	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.74e-05	0.000138	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.73e-05	0.000137	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.71e-05	0.000136	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.71e-05	0.000135	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.7e-05	0.000135	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.69e-05	0.000134	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.69e-05	0.000134	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.68e-05	0.000133	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.67e-05	0.000132	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.66e-05	0.000131	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.64e-05	0.00013	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.63e-05	0.000129	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—COMT—attention deficit hyperactivity disorder	1.62e-05	0.000129	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.62e-05	0.000128	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—MAOA—attention deficit hyperactivity disorder	1.61e-05	0.000128	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.61e-05	0.000127	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.58e-05	0.000125	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.58e-05	0.000125	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.57e-05	0.000124	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.55e-05	0.000123	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.55e-05	0.000123	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.52e-05	0.00012	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.52e-05	0.00012	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.5e-05	0.000119	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.5e-05	0.000119	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.48e-05	0.000117	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.47e-05	0.000117	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.47e-05	0.000117	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.47e-05	0.000116	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	1.46e-05	0.000116	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.46e-05	0.000116	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.46e-05	0.000116	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.45e-05	0.000115	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	1.44e-05	0.000114	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.43e-05	0.000113	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.41e-05	0.000112	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	1.38e-05	0.000109	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.38e-05	0.000109	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.37e-05	0.000108	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.36e-05	0.000108	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	1.36e-05	0.000107	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	1.35e-05	0.000107	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.34e-05	0.000106	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.33e-05	0.000105	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.33e-05	0.000105	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.31e-05	0.000103	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	1.28e-05	0.000101	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	1.27e-05	0.000101	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.26e-05	9.97e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.24e-05	9.8e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	1.17e-05	9.29e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.17e-05	9.25e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	1.17e-05	9.23e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.11e-05	8.81e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.1e-05	8.73e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.1e-05	8.72e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.1e-05	8.69e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.05e-05	8.31e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.05e-05	8.3e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	9.33e-06	7.39e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	9.01e-06	7.13e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.01e-06	7.13e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	8.86e-06	7.01e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	8.86e-06	7.01e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	8.8e-06	6.96e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.67e-06	6.86e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	8.35e-06	6.61e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	8.29e-06	6.56e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.24e-06	6.52e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.2e-06	5.7e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—EP300—attention deficit hyperactivity disorder	6.96e-06	5.51e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.86e-06	5.43e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.84e-06	4.63e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.81e-06	4.6e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.57e-06	4.41e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	5.49e-06	4.35e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	5.46e-06	4.32e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	5.42e-06	4.29e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.05e-06	4e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	5.03e-06	3.98e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.94e-06	3.91e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.59e-06	3.64e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	3.8e-06	3.01e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	3.58e-06	2.83e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	2.34e-06	1.85e-05	CbGpPWpGaD
